NeuroSense Therapeutics Ltd (NASDAQ: NRSN): To Buy Or Not To Buy, That Is The Question
After grabbing 11702.0 shares, the institutional investor is now in possession of 11702.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 0.09% having worth around $5395.0. Moreover, UBS Securities LLC increased its share by 9665.0 to have a control over 9665.0 shares. NeuroSense Therapeutics Ltd (NRSN) concluded trading […]
